DefiniGEN’s induced pluripotent stem cell (iPSC) differentiation platform generates high quality wild-type and disease cell models. We can produce highly functional human pancreatic cells predominantly composed of insulin-secreting beta cells. We provide off-the-shelf iPSC derived pancreatic cells, but we also offer the ability to model various diseases.
The cells have similar function to primary cells including donor genetics, karotype and cell metabolism. They exhibit a robust Glucose Stimulated Insulin Secretion response and they also respond to key reference drugs such as GLP-1 and Exenatide.
Pancreatic WT Pancreatic MODY3 Pancreatic Neonatal Diabetes
TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors. Cebola, Vallier , Ferrer et al. Nature Cell Biology. 2015 May;17(5):615-26.
Generation of multipotent foregut stem cells from human pluripotent stem cells. Hannan NR, Vallier L. Stem Cell Reports. 2013 Oct 10; 1(4):293-306
Inhibition of activin/nodal signalling is necessary for pancreatic differentiation of human pluripotent stem cells. Cho CH, Hannan NR, Vallier L.et al Diabetologia, 2012 Dec;55(12): 3284-95
Modelling Neonatal and MODY Diabetes in Vitro Using IPS Cell-derived human Pancreatic Beta Cells. Soares F, Santos R, Schofield C, Lowe C, Vallier L. ISSCR 2016 June 22-25.